March 24, 2023
Ono Pharmaceutical said on March 23 that its PD-1 inhibitor Opdivo (nivolumab) has won an additional indication in South Korea for the frontline treatment of certain patients with advanced esophageal cancer in combination with the CTLA-4 inhibitor Yervoy (ipilimumab) or...read more